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Abstract: Molecular docking is an established in silico structure-based method widely used in drug
discovery. Docking enables the identification of novel compounds of therapeutic interest, predicting
ligand-target interactions at a molecular level, or delineating structure-activity relationships (SAR),
without knowing a priori the chemical structure of other target modulators. Although it was originally
developed to help understanding the mechanisms of molecular recognition between small and
large molecules, uses and applications of docking in drug discovery have heavily changed over the
last years. In this review, we describe how molecular docking was firstly applied to assist in drug
discovery tasks. Then, we illustrate newer and emergent uses and applications of docking, including
prediction of adverse effects, polypharmacology, drug repurposing, and target fishing and profiling,
discussing also future applications and further potential of this technique when combined with
emergent techniques, such as artificial intelligence.
Keywords: molecular docking; drug discovery; drug repurposing; reverse screening; target fishing;
polypharmacology; adverse drug reactions
1. Introduction
The experimental screening of large libraries of compounds against panels of molecular targets,
i.e., High-Throughput Screening (HTS), has represented the gold standard for discovering biologically
active hits. However, the high costs required to establish and maintain these screening platforms
often hamper their use for drug discovery [1]. Moreover, considering the recent developments in
computer technology and the rapid increase of structural, chemical, and biological data available on
an ever-growing number of therapeutic targets, it is easily understandable how the use of in silico
approaches as chemoinformatics, molecular modeling, and artificial intelligence (AI) has significantly
increased in the last decades [2–6]. Indeed, in silico approaches now enable the virtual screening
of millions of compounds in an affordable time, thus reducing the initial costs of hit identification
and improving chances of finding the desired drug candidates. At present, several molecular
modeling techniques are available to facilitate drug discovery tasks, most of them being classified into
structure-based and ligand-based approaches.
Structure-based methods rely on the information derived from the knowledge of the 3D structure
of a target of interest, and they allow ranking databases of molecules according to the structural and
electronic complementarity of ligands to a given target [7]. In this context, molecular docking is
among one of the most popular and successful structure-based in silico methods, which help predict
the interactions occurring between molecules and biological targets [7]. This process is generally
accomplished by first predicting the molecular orientation of a ligand within a receptor, and then
estimating their complementarity through the use of a scoring function [7].
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Since its first appearance in the mid-1970s, docking has proved to be an important tool to help
understanding how chemical compounds interact with their molecular targets, and for drug discovery
and development. As a matter of fact, the number of studies reporting: (i) the use of molecular
docking to identify structural determinants necessary for efficient ligand-receptor binding, and (ii) the
development of more accurate docking methods, have heavily increased since its first appearance [7–21].
Among the first and more interesting studies on the use of docking in drug discovery and biology is
the one from Kuntz et al. in the early 1980s [13]. In this study, the authors described a computational
method enabling the exploration of geometrically feasible ligand-receptor alignments for the known
heme-myoglobin/metmyoglobin and thyroxine/prealbumin structures [13]. This study was not the
first to employ docking for predicting potential conformations of molecular complexes [9]. However, it
reported for the first time the use of a simplified function containing solely the terms “hard sphere
repulsions” and “hydrogen bonding” to describe protein-ligand interactions, which strongly differed
from previous studies [9,11,12,22]. Moreover, the authors were also the first to consider the receptor as
a solid rigid body, whose binding site is constituted by “pockets”. Interestingly, the method adopted
in this study was able to predict structures close to those of already reported X-ray complexes, and
also to find protein conformations that could be used for energy refinement and eventually design
novel ligands [13]. Since then, molecular docking underwent dramatic improvements, for example, by
employing flexible algorithms in the calculations [21,23–26]. Moreover, it also started to be used for
the design and optimization of compounds with therapeutic interest. An example of this comes from a
study of Ring et al., in which several structure-based drug design methods, including docking, were
performed to identify novel non-peptidic inhibitors of enzymes of the serine and cysteine protease
families [27]. The results achieved in this work further consolidated the use of computer-aided
structure-based drug-design methods for assisting the development of lead compounds [27].
Given the potential offered by this method, increasing efforts have been directed towards the
improvement of docking algorithms and for overcoming its intrinsic limitations [28–30]. Indeed,
major limitations characterizing docking include a restricted sampling of both ligand and receptor
conformations in pose prediction, and the use of approximated scoring functions, which very often
provide results that do not correlate with the experimental binding affinities [31,32]. Nevertheless, the
application of docking in drug design is limited to biological targets for which crystal structures are
known. Several approaches have been adopted to overcome this latter limitation. For example, the
unavailability of 3D structures is often bypassed by building homology models derived from structural
templates with highly-homologous sequences. Moreover, these methods could also be used in tandem
with molecular dynamics (MD) to further validate and refine the in silico modeled complexes [33–35].
Nevertheless, the recent progress in structural biology and crystal structure determination, which are
progressively increasing the accessibility to experimentally derived ligand-target complexes [36–39],
will certainly mitigate this issue. In silico strategies, including molecular dynamics, have also been
widely used to explore the conformational space of the investigated targets, ligands, and ligand-target
complexes, and thus better describing the dynamic behavior of ligand-target complexes and refining the
docking results [34,40,41]. More rigorous virtual screening methodologies have also been developed
to improve the docking-based ligand-target complex predictions [42–46]. Indeed, these post-docking
refinement and rescoring methods are of great interest in drug discovery because they usually
provide higher hit rates in virtual screening campaigns and allow better correlation with experimental
data [44,46].
A number of reviews discussing the role and applications of docking, and the possibilities it
could offer in drug design and development, have been reported [7,18,47–50]. However, it should be
noted that the uses and applications of docking have been changing since its first appearance. In fact,
although it was first developed to investigate molecular recognition between large and small molecules,
it is now also widely used to assist different tasks of drug discovery programs, such as hit identification
and optimization, drug repositioning, a posteriori target identification (reverse screening), multi-target
ligand design, and repositioning (Figure 1) [49,51–58]. Moreover, docking allows understanding the
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relationships between different molecular targets involved in a given disease, which is also of high
relevance for polypharmacology [59] and modern drug discovery in general.
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Figure 1. Main applications of molecular docking in current drug discovery. Molecular docking is 
currently employed to help rationalizing ligands activity towards a target of interest and to perform 
structure-based virtual screening campaigns, similarly to as when it was first developed. Besides 
these applications, it can also be used to identify series of targets for which the ligands present good 
complementarity (target fishing and profiling), some of them being potentially responsible for 
unexpected drug adverse reactions (off-targets prediction). Moreover, docking is also currently 
employed for the identification of ligands that simultaneously bind to a pool of selected targets of 
interest (polypharmacology) and for identifying novel uses for chemical compounds with already 
optimized safety profiles (drug repositioning). 
In particular, the use of this technique has broadened towards novel drug discovery horizons, 
fueled by the improvement of docking algorithms and by the increase of the publicly accessible 
information on ligands and targets. For example, thanks to the improved speed and prediction 
power, docking has also been embedded into large-scale screening protocols to identify [60], e.g.: (i) 
protein binding sites in which ligands could bind [61]; (ii) novel molecular targets of known ligands 
[54]; (iii) potential adverse drug reactions (ADRs) [62], and; (iv) ligands with novel chemotypes 
active against a given target or a set of desired targets [55]. 
In this review, we will discuss how docking methods have been used to help assisting drug 
discovery tasks, giving particular emphasis on recent drug design strategies, including 
polypharmacology, drug repurposing, target identification, and prediction of adverse drug 
reactions. 
2. Current Rational Design Approaches, Including Docking  
The possibilities offered by molecular docking in drug discovery are well established 
[3,5,7,18,47,49,50,63]. However, docking presents intrinsic limitations that limit its prediction 
performances, the most relevant being reported in the previous section. Although docking has been 
mainly used as a standalone method for drug design, it is now often integrated into workflows that 
include other computational methods, such as ligand-based, structure-based, and AI approaches 
(Figure 2) [50,64]. This helps to account for some of the most relevant limitations characterizing this 
structure-based method. 
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opti ized safety profiles (drug repositioning).
In particular, the use of this technique has broadened towards novel drug discovery horizons,
fueled by the improvement of docking algorithms and by the increase of the publicly accessible
information on ligands and targets. For example, thanks to the improved speed and prediction power,
docking has also been embedded into large-scale screening protocols to identify [60], e.g.: (i) protein
binding sites in which ligands could bind [61]; (ii) novel molecular targets of known ligands [54]; (iii)
potential adverse drug reactions (ADRs) [62], and; (iv) ligands with novel chemotypes active against a
given target or a set of desired targets [55].
In this review, we will discuss how docking methods have been used to help assisting
drug discovery tasks, giving particular emphasis on recent drug design strategies, including
polypharmacology, drug repurposing, target identification, and prediction of adverse drug reactions.
2. Current Rational Design Approaches, Including Docking
Th possib lities off red by molecular docking in drug discovery are well established [3,5,7,18,47,49,50,63].
However, docking presents intrinsic limitations that limit its prediction performances, the most relevant
being reported in the previous section. Although docking has been mainly used as a standalone method for
drug design, it is now often integrated into workflows that include other computational methods, such as
ligand-based, structure-based, and AI approaches (Figure 2) [50,64]. This helps to account for some of the
most relevant limitations characterizing this structure-based method.
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Figure 2. Integration of docking with ligand-based, molecular dynamics, binding free energy 
approaches, artificial intelligence (AI), and statistical methods. According to the available 
information, different in silico approaches can be combined with docking to generate integrated 
workflows with improved prediction performances. Different approaches can also be combined to 
integrate docking (e.g., molecular dynamics and binding free energy estimations can be combined 
with docking to improve virtual screening results). Likewise, different approaches can also be 
applied at different phases of the screening workflow to improve docking predictions. For example, 
molecular dynamics could be combined with AI-based methods to identify suitable receptor 
conformations for docking. Then, ligand-based approaches could be applied for rescoring the 
predicted docking poses [50,65,66]. 
In particular, ligand-based approaches have been used to select suitable protein conformations 
for docking screenings [67–70]. The ability of docking to discriminate active compounds from 
decoys can strongly depend on the used protein structures and the similarity degree of the screened 
ligands with those co-crystallized in the employed target conformations [69–72]. In this regard, 
Broccatelli et al. recently reported a study in which different ligand-based methods have been 
applied for the selection of protein conformations for docking, comparing the performance of 
different protocols in retrieving known CDK2 inhibitors within two distinct datasets [69]. Similar 
considerations arose also from the more recent studies of Xu et al. [73] and Kumar et al. [74], in 
which the authors successfully predicted the affinity and binding mode of a series of Hsp90 [73] and 
farnesoid X receptor ligands [74], by combining ligand-based approaches with docking. 
Ligand-based approaches have also been used to improve the prediction performance of 
docking screenings, e.g., by measuring the 3D similarity between the binding conformation 
predicted by docking and the experimental conformation of the ligand co-crystallized in the 
employed protein conformation [75]. For example, Perryman et al. [76] demonstrated that 
pharmacophore-based rescoring can improve docking predictions in blind virtual screenings. 
Similar results were also obtained by Jiang et al. [77], who retrospectively evaluated the performance 
of DOCK [78,79] against three clinical drug targets (EGFR, IGF-1R, and HIVgp41). According to the 
obtained in silico results, in particular, the authors demonstrated that the combination of the 
standard DOCK energy function with an especially devised pharmacophore-based scoring function 
outperformed single approaches in discriminating active from inactive compounds [77]. Similarly, 
3D- and shape-based similarity have also been used in tandem with docking for pose selection and 
virtual screening [80,81]. In particular, Kumar et al. demonstrated that 3D shape similarity matching 
is a promising approach for the selection of docking poses [81]. Moreover, they also observed that 
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Then, ligand-based approaches could be applied for rescoring the predicted docking poses [50,65,66].
In particular, ligand-based approaches have been used to select suitable protein conformations
for docking screenings [67–70]. The ability of docking to discriminate active compounds from decoys
can strongly depend on the used protein structures and the similarity degree of the screened ligands
with those co-crystallized in the employed target conformations [69–72]. In this regard, Broccatelli
et al. recently reported a study in which different ligand-based methods have been applied for the
selection of protein conformations for docking, comparing the performance of different protocols in
retrieving known CDK2 inhibitors within two distinct datasets [69]. Similar considerations arose also
from the more recent studies of Xu et al. [73] and Kumar et al. [74], in which the authors successfully
predicted the affinity and binding mode of a series of Hsp90 [73] and farnesoid X receptor ligands [74],
by combining ligand-based approaches with docking.
Ligand-based approaches have also been used to improve the prediction performance of docking
screenings, e.g., by measuring the 3D similarity between the binding conformation predicted by
docking and the experimental conformation of the ligand co-crystallized in the employed protein
conformation [75]. For example, Perryman et al. [76] demonstrated that pharmacophore-based rescoring
can improve docking predictions in blind virtual screenings. Similar results were also obtained by Jiang
et al. [77], who retrospectively evaluated the performance of DOCK [78,79] against three clinical drug
targets (EGFR, IGF-1R, and HIVgp41). According to the obtained in silico results, in particular, the
authors demonstrated that the combination of the standard DOCK energy function with an especially
devised pharmacophore-based scoring function outperfor ed single approaches in discriminating
active from inactive compounds [77]. Similarly, 3D- and shape-based similarity have also been used
in tandem with docking for pose selection and virtual screening [80,81]. In particular, Kumar et al.
demonstrated that 3D shape similarity matching is a promising approach for the selection of docking
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poses [81]. Moreover, they also observed that docking-based scoring could be conveniently combined
with 3D shape similarity to improve virtual screening results [81]. Anighoro et al. recently explored an
alternative path to force field-based scoring functions to improve the ranking of candidate ligands
of four therapeutic drug targets (DHFR, GR, VEGFR2, and HIV1PR) [80]. According to the obtained
in silico results, in particular, the authors demonstrated that the use of 3D similarity approaches
for rescoring docking poses could improve ranking lists and hit-rates in structure-based virtual
screenings [80]. Nevertheless, methods based on the comparison of ligand-target binding features,
e.g., through the use of the protein-ligand interaction fingerprints (PLIFs), have also successfully been
explored for rescoring docking results [82–84].
Standing on current literature data, the combination of ligand-based and structure-based
approaches allows to heavily improve the prediction power, and thus hit-rates, in virtual screening
campaigns. However, it should also be noted that the possibility to apply ligand-centered methods
in tandem with docking could be explored solely for those targets that have at least one reported
co-crystallized ligand [70,81].
Structure-based approaches, such as molecular dynamics and binding free energy estimations,
have also widely been used in combination with docking to improve virtual screening results. In
particular, MD allows to evaluate residues flexibility in the target binding site, as well as to explore larger
conformational changes potentially accessible to a given protein [33,34,41]. Therefore, it represents
an efficient tool to identify receptor conformations for docking [70,85] and to evaluate the stability
of the predicted complexes [33,34]. The possibilities offered by MD in prospective in silico screening
are particularly appealing for flexible targets with a limited number of reported crystallographic
conformations. An example of this comes from a study of Wang et al. [86], who have performed
classical MD simulations in explicit solvent to evaluate the stability of the α-helical structure of amyloid
β42 (Aβ42), thus identifying a representative protein conformation to perform virtual screening of
commercially available compounds [86]. This approach allowed the selection of a set of compounds to
be experimentally validated, five of them showing inhibition of Aβ42 aggregation in the micromolar
range. Moreover, one of the identified hits also displayed inhibition of BACE1, which plays a key role in
the pathogenesis of Alzheimer’s disease [86]. Similar considerations could also be drawn from a more
recent work of Spyrakis et al. [87], who demonstrated that standard molecular dynamics, clustering,
and linear discriminant analysis (LDA) can be integrated to substantially improve structure-based
virtual screening results. In this study, in particular, the authors firstly performed MD simulations
on three flexible targets (the purine nucleoside phosphorylase PNP, the A2A receptor, and the ABL1
tyrosine-protein kinase) in search of novel protein conformations. Then, they performed clustering via
the K-medoids method on the calculated molecular dynamics trajectories [88] to identify MD-derived
representative conformations of the investigated targets. Finally, the performance of the FLAP docking
program [89] in discriminating active from inactive compounds extracted from DUD-e [90], which
is a database useful to benchmark and validate docking protocols, was assessed. LDA was used to
automatically select the best combination of protein templates among MD-derived representative and
experimentally observed structures yielding the best screening results.
Altogether, the discussed examples demonstrated how the inclusion of classical MD in
docking-based protocols could improve virtual screening performances, especially when dealing
with highly flexible targets [86,87]. More advanced enhanced sampling techniques, such as umbrella
sampling [91], metadynamics [92], and replica exchange MD [93], can also be applied to identify
protein conformations for docking screening. Indeed, these techniques, which allow exploring a
protein conformational landscape far larger with respect to that of standard MD simulations, have
already been applied to study protein flexibility and function [94–101] and to identify additional
binding pockets that could be exploited for the design of novel inhibitors [102,103]. However, it should
be noted that the application of these advanced methods is computationally more demanding with
respect to standard MD.
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Combinations of docking with standard molecular dynamics and binding free energy estimations
have also been recently explored to account for protein flexibility and to improve virtual screening
predictions, respectively [44,46,104–106]. In fact, results of currently available docking algorithms
might be affected by poor conformational sampling [7,31]. Moreover, they might provide inaccurate
binding energy estimations [7,23] derived by approximate scoring functions [28,107,108]. Indeed,
several scoring functions based on different algorithms and concepts, which can be classified into
empirical, knowledge-based, and force field-based, have been developed for docking so far [28,30].
However, all of them employ a series of mathematical functions with approximations that do not
accurately take into account some thermodynamic elements of the binding energy (e.g., entropy
changes upon binding and solvation effects), to allow the fast prediction of ligand-target complex
affinity [28,30]. Several approaches have been adopted to account for these issues so far. For example,
Rastelli et al. [42] developed BEAR (Binding Estimation After Refinement), a post-docking tool that first
performs MD-based structural refinement of ligand-protein complexes, and then predicts their binding
free energy with the MM-PBSA and MM-GBSA methods [109]. Indeed, several studies, showing the
improvements that the MM-PBSA and MM-GBSA methods, and BEAR provided, both in a posteriori
and prospective virtual screenings, have been reported [44,46], demonstrating that the application of
these approaches heavily improves docking results.
The more advanced and computationally expensive free energy prediction methods Free Energy
Perturbation (FEP), Thermodynamic Integration (TI), and funnel metadynamics can also be used for
the post-processing of docking results [110–112]. For example, Lee et al. [113] successfully applied
a computational workflow that integrates molecular docking, MD simulation, and FEP calculations
to predict the binding mode and ligand-protein affinity of a series of MDM2 and MDMX inhibitors,
discussing also virtues and vices of the adopted protocol. More recently, Bhati et al. [114] proposed a
method that combines MD and TI and was able to provide accurate binding affinities. The performance
of their protocol was validated on five well-characterized proteins involved in several physiological
processes. However, although the latter approaches are more accurate than docking scoring functions,
or even other free energy methods as MM-PBSA and MM-GBSA, in predicting ligand-protein affinity,
they are computationally expensive, therefore potentially less suitable for the screening of large libraries
of compounds [115].
Very recently, statistical and Artificial Intelligence approaches have also gained a foothold in drug
discovery [64]. In fact, these methods allow to easily exploit the ever-growing source of information
contained in publicly available structural, chemical, and bioactivity databases, leading to more accurate
binding affinity predictions. In particular, machine learning (ML) approaches, including Random
Forest (RF) [116] and Support Vector Machines (SVM) [117], have been applied for improving the
docking-based binding affinity predictions [29,118]. For example, Xie et al. [119] successfully developed
and applied a computational workflow integrating SVM-based classification with docking calculations
to identify novel inhibitors of the c-Met tyrosine kinase. In particular, the authors firstly developed and
validated an SVM classification model able to discriminate between active and inactive c-Met ligands.
Then, they compared the performances of the developed SVM-based model with respect to those of
docking, and then the combination of the two methods. The combined SVM-model/docking approach,
which provided the best hit-rates and enrichment factors, was finally used to screen a large library
of ligands, leading to the identification of eight active compounds among those selected [119]. SVM
techniques were also implemented in ensemble schemes to improve docking predictions on flexible
targets. For example, Leong et al. [120] recently reported the development and retrospective validation
of tailored SVM classification models able to improve docking posing and scoring predictions against
the N-methyl-D-aspartate GluN1 receptor. In particular, the authors firstly developed SVM-based
posing models by performing docking calculations on ligands reported in complex with seven crystal
structures of the N-methyl-D-aspartate GluN1 receptor. Then, they derived a series of SVM-based
scoring models from the poses predicted with the same procedure, for a dataset of compounds with
reported bioactivity data. Finally, the authors performed a retrospective validation of the newly
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developed SVM models by screening a further set of compounds, demonstrating that their approach
outperformed standard docking in accurately predicting ligand poses and binding affinities [120].
Machine learning approaches have also been used to improve docking scoring functions.
For example, Ballester et al. [121] developed among one of the first ML-based scoring function,
called “RF-Score”, which uses Random Forest to improve protein-ligand binding affinity predictions.
In particular, the authors firstly developed an RF-based scoring function by using different sets of
ligand-protein complexes with known activity data reported within the PDBbind database [122].
Then, they compared the performance of “RF-Score” with that of other sixteen scoring functions
implemented in currently available docking programs, demonstrating that it improved docking results
both in virtual screening and lead optimization tasks and that its performances are independent
from the employed training sets [121]. Similar considerations come also from a more recent study
of Wang et al. [123], who developed a novel scoring function by re-parameterizing the one already
implemented in AutoDock Vina [124], with random forest. According to the achieved results, the
authors demonstrated that their method outperformed standard docking programs in predicting scores
that correlate with experimentally derived binding affinities. Moreover, they also demonstrated that
the prediction performances of their scoring function improved with the use of larger datasets for the
RF-based scoring function correction [123].
Deep learning (DL) approaches have also been studied to improve docking results. For example,
Pereira et al. [125] recently reported an approach based on Convolutional Neural Networks (CNN)
called “DeepVS”, which learns the features relevant for the binding of a ligand to a target under
study, given a set of docking results. In particular, they firstly developed a scoring function that
generates DL-based docking scores based on structural data describing a ligand-protein complex
(i.e., the atom types and their partial charges, distance between the atoms, and the amino acid
types). Then, to demonstrate that the developed scoring function can provide improved results, the
authors performed extensive validation screenings on forty different datasets reported in the DUD-e
database [90]. According to the reported results, the newly developed “DeepVS” scoring function was
able to provide higher screening performances with respect to those of standard scoring functions.
Interestingly, this study was the first to report the application of deep learning for rescoring docking
poses without requiring human-defined parameters, thus making it a particularly appealing approach
for unsupervised, large scale, virtual screening campaigns [125].
Less sophisticated, but still robust, statistical techniques, such as score distribution data analysis,
have also been examined. In particular, Wang et al. [126] recently reported the application of score
distribution data analysis and docking for protein structure selection. Moreover, the adopted approach,
which can be employed for a variety of virtual screening purposes, also allowed to successfully identify
off-targets activities for 43 anticancer drugs approved by Food and Drug Administration (FDA) [126].
Although the recent introduction of statistical techniques allowed improving results of docking
screenings, their applicability heavily depends on the availability of structural, chemical, or bioactivity
data. Therefore, such approaches may not represent the optimal choice to improve docking prediction
performances when dealing with recently identified, or not yet thoroughly studied, therapeutic targets.
3. Reverse Screening for Target Fishing and Profiling
Docking has also been recently used for a variety of other purposes in drug discovery. In particular,
Reverse Docking (RD), which allows predicting the biological targets of a molecule of interest [127],
represents a valuable approach for computational target fishing and profiling [60].
Several docking approaches and algorithms are available to enable the reverse screening of a ligand
towards a library of protein structures and to assess their binding affinity. However, the application of
these approaches requires suitable libraries of targets [60,127]. Indeed, several databases are currently
available to help performing RD screenings. Among one of the most known databases to facilitate
computational target identification is PDTD [128], which provides information about protein structures,
diseases, biological functions, and drugs. Moreover, tailored libraries of targets can also be manually
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built upon publicly available databases of crystal structures and binding pockets, such as the Protein
Data Bank (PDB) [129], sc-PDB [130], Pocketome [131], and Therapeutic Target Database (TTD) [132].
In particular, the PDB [129] and TTD [132] databases represent well-known reservoirs of information
developed to help facilitating computational, molecular and structural biology, and to provide data
about targets and diseases, respectively. The sc-PDB [130] and Pocketome [131] databases were
instead developed for comparing protein cavities, better describing the ligand-protein pharmacophoric
properties and for target identification via pocket-based virtual screening, and to benchmark docking
screenings, respectively. Although these libraries of targets were not specifically developed for target
fishing and profiling, they allow covering large structural spaces of the known proteome. However, it
should be noted that the preparation of such libraries is a time-consuming task because each structure
in the databases requires to be properly prepared for the docking calculations [60,127].
In RD screenings, potential targets of a ligand can be ranked according to scoring functions
implemented in commonly used docking programs as Glide [133,134]. For example, Park and
Cho [135] performed an extensive RD screening on a library of disease-related proteins, including
entries from PDTD and around 500 kinases, to identify potential targets for 26 ginsenosides. Results
of the screenings allowed the authors to identify potential ligand-protein interactions for some of
the investigated natural products with anticancer targets, such as MEK1, EGFR, and Aurora A [135].
Interestingly, although the predicted ligand-protein interactions were not experimentally validated,
anticancer activity has been reported for some of the investigated ginsenosides [136]. Moreover,
the authors identified potential interactions with targets as acetylcholinesterase, human Carbonic
Anhydrase II, and glutamate dehydrogenase, which might be responsible for cholinergic side effects and
nephrotoxicity [135]. Although being extensively used in RD screenings, results of standard docking
scoring functions can heavily depend on the investigated targets, or even on the employed structural
conformations of a given protein. Therefore, normalization of the scores is generally recommended to
avoid target-dependent biased results [60,127,137].
Integration of docking with more sophisticated ML-based methods has also very recently been
explored for target predictions [138,139]. An example is a study of Nogueira and Koch [139], in
which SVM and Neural Networks (NN) models were used to improve the results of reverse docking
screenings, pre-processed with the PADIF (Protein Atom Score Contributions Derived Interaction
Fingerprint) method [82]. In particular, the authors firstly built datasets of compounds for twenty
biological targets with already reported bioactivity data on ChEMBL [140] and X-ray crystal structures.
Then, for each target, they developed SVM and NN machine learning models able to discriminate
active from non-active compounds based on the docking-derived PADIFs. Finally, they retrospectively
validated their models, achieving notable prediction performances, both in terms of target ranking
and on multi-target selectivity predictions [139]. Although these structure-based approaches might
present several advantages over ligand-based methods and standard docking, they are time and
computationally demanding. Moreover, they also need a large amount of bioactivity data to train
the models, which sometimes could not be available for some of the targets under study. However,
considering the recent advances in hardware and software [141,142] and the increased amount of
publicly available bioactivity data, ML-based approaches will certainly play a central role in future
target identification and profiling tasks.
Consensus approaches based on RD have also recently been reported for target fishing [143]. In
particular, Lapillo and coworkers [143] performed an extensive benchmarking study on 13 different RD
screening procedures to identify which method performed better in predicting targets for known ligands.
Moreover, they also explored a docking-based consensus approach to improve RD target prediction
performances [143]. According to the results reported in this study, target-fishing performances of
the different docking procedures ranged around 25% and 35% (in terms of true predictions) for single
approaches, and 36% for the consensus. However, this study also showed that the results of the applied
RD approaches could be dependent on the features of the investigated proteins binding site [143].
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As the set-up of reverse docking screening workflows requires more efforts and longer preparation
with respect to standard virtual screening, various tools and web platforms have also been recently
developed to facilitate RD. Most of them entrust in already compiled libraries of disease-relevant
targets and implement standard programs (e.g., DOCK [79], AutoDock [144], and AutoDock Vina [124])
for performing reverse docking calculations. Therefore, they enable researches to easily identify the
biological targets of their molecules of interest, even without massive computational efforts. Among
the most relevant programs and web platforms currently in use for docking-based reverse screening are
INVDOCK [145], TarFisDock [54], ACTP [146], and idTarget [147], which have been widely employed
for target fishing and profiling in several studies, and for different purposes [148–152]. In particular,
INVDOCK [145] is a software based on docking, which has been devised for the identification of
potential targets for drugs, candidates under clinical trials and ligands, and to facilitate the study of
their potential side effects. TarFisDock [54], ACTP [146], and idTarget [147] are web platforms that
enable remote RD screening of a given ligand to a set of protein structures. In particular, TarFisDock [54]
and idTarget [147] enable the screening of a given ligand to a set of proteins available within the PDTD
and PDB by using the DOCK [79] and MEDock [153] docking programs, respectively. Similarly, the
ACTP [123] web server enables the screening of a ligand by using the Libdock docking protocol [154].
However, reverse docking analyses of this latter web platform are restricted to a set of autophagy-related
protein targets [146].
The utility of these platforms for drug discovery has already been reviewed elsewhere [60,127].
However, considering the relevance of the topic and the improvements in:
(i) currently available computational techniques and software in general, which allow to more
accurately screen larger databases;
(ii) hardware facilities, which enable a faster screening of ligands to targets, to a larger public, and;
(iii) crystallography [36–39] and homology modeling [155,156] techniques, which allow expanding
our knowledge on structural biology;
we envision that further advances in reverse docking will certainly play a central role for target
fishing and profiling of ligands in future drug discovery.
4. Prediction of Adverse Drug Reactions
The early identification of drug side effects is of high interest in drug discovery. In fact, it is
well known that most of the drug candidates fail clinical trials because of side effects deriving from
unexpected interactions with off-targets. Moreover, post-marketing side effect analyses on approved
drugs (i.e., pharmacovigilance) are also important because they allow revealing potential safety risks
that often could not be detected within clinical trials [157]. Several computational approaches are
currently available to assist this task [158–161]. However, most of them require a satisfactory amount
of bioactivity data, or of already reported adverse effects as an input for the model training [158–161].
Interestingly, molecular docking needs solely the structural information of the targets to perform its
predictions. Therefore, it represents a valuable approach to predict potential side effects of compounds
at early phases of clinical and pre-clinical developments, or on marketed drugs with not yet reported
exhaustive drug labels and bioactivity records. Indeed, applications of RD screening for identifying
drug adverse effects have already been reported in the literature [127,149,162–164]. For example,
Ji et al. [149] performed RD screenings to identify potential side effects for a series of anti-HIV drugs,
highlighting several proteins whose modulation has already been associated with adverse reactions.
Indeed, more than 85% of their target predictions found correspondence with clinical evidence reported
in the literature [149]. However, it should also be noted that some of the targets known to be modulated
by the investigated anti-HIV drugs could not be predicted within their study, due to the lack of
structural information in the analyzed database [149] or because of intrinsic limitations of the adopted
screening approach. Altogether, the results reported in this study demonstrated that docking-based
reverse screening can be an efficient tool for identifying putative adverse drug reactions. However,
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the obtainment of good performance predictions is tightly related to the information reported in the
analyzed database of targets. Databases developed to facilitate adverse reactions recognition for drugs
have already been reported, SIDER being one of the best known [165]. In particular, SIDER contains
more than 140,000 drug-ADR pairs registered in clinical trials and post-marketing surveillance [165],
which could facilitate the identification of target activities responsible for side effects. However,
databases of targets can also be developed on purpose for performing more focused RD-based ADR
analyses, as previously discussed for target fishing and profiling.
More sophisticated screening approaches based on consensus docking [166], or combination
with machine learning techniques [138], have also been explored to improve the predictions of drug
adverse events. For example, Jaundoo et al. [166] recently applied a consensus docking approach using
three different programs, namely AutoDock, AutoDock Vina, and Glide, to predict putative adverse
reactions of a set of 43 drugs approved by FDA for the treatment of Gulf War Illness (GWI)-related
symptoms. Indeed, the authors performed their analyses to identify side effects potentially arising by
the combined use of some of these drugs, suggesting caution for some of them. Moreover, strengths
and limitations related to the use of consensus approaches with respect to standard docking were also
discussed by the authors [166].
Combinations of docking with statistical approaches have been applied for predicting off-target
activities of already reported drugs (see above) [126]. Moreover, a combination of docking with
machine learning models has recently been explored. For example, Luo et al. [138] performed an
extensive study on more than 1200 compounds extracted from DrugBank against 600 human proteins
for predicting or rationalizing drug adverse effects. In particular, the authors firstly performed docking
calculations with AutoDock Vina for assessing binding modes and affinity scores of the ligand-protein
complexes, and they built ML-based models upon adverse reactions data reported within the SIDER
database [165]. Then, they performed side effect predictions by comparing the evaluated ligand-protein
scores with the trained ML models. Their analyses resulted in the prediction of 1533 putative adverse
reactions and provided potential explanations on the biological mechanisms behind some of already
reported drug side effects (e.g., irinotecan that induces decreased libido) [138], demonstrating that
ADRs predictions on a large scale are feasible with computational workflows that integrate docking.
Based on the results of the aforementioned studies, it can be argued that consensus approaches
with other molecular modeling methods, or integration with AI approaches, will play a pivotal role
in future docking-based side effects prediction, allowing to overcome the main limitations currently
affecting docking programs.
5. Polypharmacology
To avoid potentially harmful side effects, the pharmaceutical industry focused on the development
of highly selective drugs. However, the high attrition rates in the late stages of clinical trials due to a
lack of therapeutic efficacy have moved modern drug design towards polypharmacology, which refers
to the identification of ligands that hit a set of selected, therapeutic-relevant targets [57,59,167,168]. In
this context, molecular docking can provide valuable opportunities because it allows the identification
of chemical scaffolds that efficiently and simultaneously bind to a pool of selected targets of interest.
Indeed, several studies related to the use of docking for the design of novel multi-target ligands
have already been reported [53,169,170]. Moreover, its utility for de novo polypharmacology design
has also been reviewed [57,168,171,172]. The design of multi-target ligands on rational grounds
is challenging [57]. Moreover, the selection of protein conformations to be used for docking can
heavily affect the success of the design [70]. This is especially true when dealing with targets with
structurally distant binding sites. Considering how difficult it can be to design multi-target ligands,
docking is now generally applied in combination with other in silico approaches. In particular,
several studies reporting the identification of multi-target ligands are based on the combination of
docking screening with pharmacophore modeling [53,169,172]. For example, we recently reported the
identification of the first Hsp90/B-Raf dual inhibitors, demonstrating that sub-structure pre-filtering
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and pharmacophore-guided docking can be efficiently combined to search for polypharmacology
ligands that bind to structurally unrelated targets [53]. However, workflows integrating docking
with other in silico techniques have also been pursued for de novo multi-target drug design and
polypharmacology in general [70,171,173]. For example, Selvam et al. [173] recently reported a study
in which a combination of MD, probe mapping, and docking approaches was applied to investigate
the selectivity of multi-target ligands towards a set of bioaminergic G-protein-coupled receptors [173].
The results showed that combined workflows, including docking, can be used to guide the design of
selective, potentially safer, multi-target molecules able to circumvent side effects commonly associated
with antipsychotic drugs. Moreover, the study also demonstrated how different in silico approaches
could be efficiently combined to identify structural peculiarities of disease-related targets, for which
selective ligands are not yet reported [173].
Web tools and platforms based on docking are also available to explore polypharmacology and
for identifying multi-target activities of ligands, such as the Computational Analysis of Novel
Drug Opportunities (CANDO) platform [174,175], DRAR-CPI [176], and DPDR-CPI [177]. In
particular, CANDO is a multicomponent platform, including molecular docking, that allows predicting
potential multi-target interactions of compounds, whereas DRAR-CPI [176] and its upgraded version
DPDR-CPI [177] are two web servers that allow identifying candidate targets for a given molecule, and
also enable drug repositioning.
Considering the number of computational tools available for the in silico screenings and the
challenges that must be faced in a multi-target drug discovery campaign, the best combination of
methods should be selected, case by case, upon the available data on the targets [57,172], and hardware
and software facilities.
6. Drug Repositioning
Drug repositioning, or repurposing, represents an established drug discovery approach that
allows identifying novel therapeutic uses for already approved drugs, candidate compounds under
clinical evaluation, natural products, or already synthesized ligands in general [178]. Given the wealth
of information reported on ligands, targets and diseases into publicly available databases, increasing
efforts have been made on the application of in silico repositioning-based discovery strategies over the
last decades. Indeed, in silico repositioning approaches have already demonstrated to provide novel
valuable opportunities for drug discovery and development [65,179–183].
In this context, molecular docking has become among one of the most popular computational
approaches to repurpose compounds towards novel therapeutic targets. For example, docking can
be applied in reverse screening approaches to identify novel molecular targets for known ligands,
based on their structural complementarity [127,184]. Docking allows virtually screening databases
of approved drugs, natural products, or already synthesized compounds into one or more biological
targets of interest in an affordable time. An example of this comes from a study of Kinnings et al.,
who performed extensive structure-based studies on nine different Mycobacterium tuberculosis InhA
structures to evaluate whether the entacapone and tolcapone drugs, approved for the treatment
of Parkinson’s disease, might be repurposed against tuberculosis [51]. Their results allowed the
identification of entacapone as a promising lead compound against resistant strains of Mycobacterium
tuberculosis [51]. Moreover, this study also demonstrated that the same drug could be potentially
used for the treatment of unrelated disorders, e.g., Parkinson’s disease and tuberculosis [51,185,186].
On the same line, Dakshanamurthy et al. [187] recently performed extensive docking-based virtual
screenings on a subset of compounds taken from the DrugBank [188,189], BindingDB [190], and
FDA (https://www.fda.gov/) databases against several X-ray crystal structures of human proteins
reported in the Protein Data Bank [129]. According to the reported results, the authors discovered
that the anti-parasitic drug mebendazole is also an anti-angiogenic VEGFR2 inhibitor. Moreover,
they also successfully discovered that the COX-2 inhibitor celecoxib and dimethyl celecoxib bind to
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Cadherin-11, which is a protein mediating calcium-dependent cell-cell adhesion that plays a crucial
role in rheumatoid arthritis [187].
Despite their great potential for drug discovery [191–193], naturally occurring molecules have
very seldom been explored for drug repositioning. Indeed, repositioning strategies based on the
integration of chemocentric target identification with docking analyses have been recently explored for
identifying novel therapeutic uses of natural compounds. For example, we have recently searched
for novel therapeutic targets for the two non-psychoactive cannabinoids cannabigerol (CBG) and
cannabichromene (CBC), by integrating shape-based similarity screening with rigid and flexible
docking calculations [53]. In particular, in this study, a computational shape-based similarity screening
was firstly performed within the DrugBank database. This analysis allowed the identification of
InhA, which is an enzyme studied for the development of anti-tubercular drugs, as a potential target
for repositioning of both CBG and CBC. Then, extensive docking analyses of the two cannabinoids
were performed in the InhA binding site. Interestingly, docking calculations predicted that CBG,
but not CBC, is a good candidate for the inhibition of InhA, a finding that was later confirmed by
subsequent experimental in vitro assays. Altogether, results of this approach, which can be applied to
repurpose both natural products and synthetic ligands, clearly demonstrate how molecular docking
and ligand-based methods could complement each other in providing more accurate drug repositioning
predictions [53]. The combined application of docking with machine learning approaches has also
been explored for drug repurposing [194]. Moreover, molecular docking has also been efficiently
integrated into web-based tools to enable remote structure-based virtual screenings of given libraries of
compounds [195–197] and for drug repurposing predictions [176,177]. For example, Lagarde et al. [196]
recently reported a retrospective repurposing screening on a curated library of already approved
drugs by using the MTiOpenScreen docking web service [195]. In particular, the authors firstly built
three different libraries of purchasable compounds containing approved drugs (“Drugs-lib”), food
constituents (“FOOD-lib”), and natural products (“NP-lib”). Then, they performed docking screenings
with the MTiOpenScreen web service into the developed “Drugs-lib” library to evaluate whether
the adopted protocol was able to identify five approved ligands, for which drug reposition against
cancer-related targets have already been reported. The performed analyses were able to identify the
investigated drugs within the first 1500 top-scored ligands in all of the performed screening campaigns,
demonstrating that the adopted protocol might be efficiently used to repurpose already marketed
compounds [196].
Based on these promising results, docking represents a valuable approach also for predicting new
therapeutic indications for already approved drugs, natural compounds, and already synthesized
ligands, especially when used in tandem with other computational methods, such as ligand-based
similarity approaches.
7. Concluding Remarks
Since its first appearance in the mid 1970′s, molecular docking has represented a unique in
silico tool to assist drug design and discovery. However, beyond the applications for which it was
originally developed, docking is now also widely employed to assist a variety of other drug discovery
tasks, such as the identification of novel chemical scaffolds within large libraries of compounds, to
perform in silico target fishing and profiling for drug repositioning, polypharmacology, prediction
of adverse effects and beyond, as described in this review article. Being a versatile tool, docking
will certainly find application also in other fields of drug discovery. Moreover, docking has been
successfully embedded within automated workflows for the screening of large libraries of compounds
and targets [54,145–147,195,198]. Of course, the recent advancements in the field of high-performance
computing played a key role in this respect. For example, they enabled the in silico screening of
millions of compounds in an affordable time [141,142]. Moreover, the recent advancements on Graphics
Processing Units (GPUs) have also provided remarkable improvements, both in data-driven drug
discovery and in molecular dynamics simulations [34,199]. Indeed, GPU calculations enabled a large
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exploration of the conformational landscape potentially accessible to proteins, in shorter times with
respect to CPUs [200]. Finally, GPU computing made big data-driven computation tasks accessible to a
larger public [201], and it is expected to play a prominent role, not only in docking but in future in
silico drug design in general [202].
The modalities by which docking is used to assist the different tasks of drug discovery have also
changed along the years. In particular, although it was initially developed and used as a standalone
method, docking is now mostly employed in combination with other computational approaches
within integrated workflows. This allows to overcome some of the most relevant intrinsic limitations
characterizing molecular docking, such as the non-exhaustive conformational sampling and the
use of approximate scoring functions [7,31,32,46]. The application of combined approaches usually
results in improved prediction performances and allows to better exploit the information coming
from different sources. Indeed, applications of combined workflows, including docking, have been
explored to assist different tasks of drug discovery. For example, docking has been used in tandem with
ligand-based, molecular dynamics, binding free energy calculations, and AI approaches to improve
the prediction performances in de novo virtual screening, as well as to assist target fishing, ADRs
prediction, polypharmacology, and drug repurposing, as discussed. However, one should be aware
of the fact that each computational method has its limitations, which might hamper its integration
with docking in combined workflows, or even reduce the prediction power of the adopted protocol.
For example, methods that provide predictions upon already available bioactivity and chemical data
(e.g., AI techniques) may not be the best approach to integrate with docking for less-characterized
molecular targets. Likewise, ligand-based approaches might not represent the optimal choice for
improving docking predictions when a sufficient number of ligands for the target(s) under study is not
available. However, when the combination is feasible, these methods demonstrated to heavily improve
docking predictions, both in terms of hit-rates and enrichment factors. On the contrary, molecular
dynamics and binding free energy estimations could help improving docking predictions even for
less-characterized targets, for example, through the identification of conformational ensembles to be
used for structure-based analyses [85], and to more accurately evaluate the ligand-protein binding
affinity [46]. Considering the number of in silico tools and techniques currently available, there are still
countless opportunities for docking to be explored in integrated workflows. Moreover, their integration
will also be facilitated by the continuous improvements in hardware and software engineering, as
discussed. Besides, novel valuable opportunities for data and methods integration will certainly come
along the increase of the publicly available structural, chemical, and biological information, and its
implementation within databases, web platforms, and automated workflows. Further efforts should be
directed toward a better integration of the different approaches with the publicly available information
reported in these databases. This is expected to provide novel valuable opportunities in future drug
discovery and development and, in particular, in the design of challenging and innovative drugs
(i.e., multi-target ligands), as well as in assisting ligand profiling and repositioning. Considering
the high attrition rates characterizing drug discovery [203,204], the possibilities offered by docking
in combination with the approaches outlined here will be important to reduce time and costs in
both the development of clinical candidates with better safety profiles (target profiling and ADRs
findings) and for the identification of novel applications of already known drugs (target profiling and
drug repositioning).
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